Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

NCT06995872 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

40

Enrollment

NIH

Sponsor class

Conditions

Neuroblastoma

Interventions

DRUG: rhIL-15
DRUG: Dinituximab
DRUG: Temozolomide
DRUG: Irinotecan Hydrochloride

Sponsor

National Cancer Institute (NCI)